Amorphous B-RAF Inhibitor Dispersion for Stable Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing B-RAF kinase dimer inhibitor Compound 1 result in significant dimer impurity formation, poor solubility, hygroscopicity, and low bioavailability, making large-scale production challenging and costly, with existing solid dispersions failing to provide stable amorphous formulations.
Innovation Solution
A stable amorphous solid dispersion of Compound 1 with hydroxypropyl methylcellulose acetate succinate (HPMCAS) using microprecipitated bulk powder (MBP) technology, achieving high bioavailability, long-term stability, and pharmaceutical processability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If column chromatography is used to remove dimer impurity, then purity is improved, but manufacturing cost and complexity increase significantly
Solution Approach 1:
The patent extracts and removes the dimer impurity through optimized recrystallization processes and selective precipitation techniques, eliminating the need for complex column chromatography. The impurity is separated based on solubility differences and crystal lattice formation preferences, achieving high purity through simpler unit operations.
Solution Approach 2:
The patent changes critical process parameters including solvent composition, temperature profiles, pH values, and addition rates to control impurity formation and facilitate its removal. By optimizing these parameters, the process achieves high purity product without requiring expensive chromatographic separation equipment.
2Manufacturing precision
If recrystallization is used to remove dimer impurity, then purity is improved, but impurity removal is insufficient due to low solubility
Solution Approach 1:
The patent introduces intermediary substances including co-solvents, complexing agents, and seeding crystals that facilitate the selective removal of dimer impurity. These intermediaries modify the solubility behavior and crystal growth kinetics, enabling efficient separation of the impurity from the main product through recrystallization.
3Stability of the object's composition
If crystalline form is used, then stability is improved, but solubility and bioavailability deteriorate
Solution Approach 1:
The patent utilizes phase transition techniques including amorphization, polymorphic conversion, and eutectic formation to create a solid state formulation that maintains stability while enhancing solubility. The compound is converted from a stable crystalline form to an amorphous or metastable polymorphic form that exhibits superior dissolution properties and bioavailability.
Solution Approach 2:
The patent creates composite formulations by combining the compound with excipients, surfactants, or co-crystals that enhance solubility and bioavailability while maintaining stability. The composite material leverages synergistic interactions between components to simultaneously improve both stability and dissolution characteristics.
4Stability of the object's composition
If crystalline form is used, then stability is improved, but hygroscopicity increases
Solution Approach 1:
The patent employs protective coatings and encapsulation strategies that create a barrier between the compound and environmental moisture. These protective layers are applied to the solid state formulation to prevent hygroscopic uptake while maintaining the stability benefits of the crystalline or amorphous form.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersion exhibits over 90% oral bioavailability, extraordinary long-term physicochemical stability, and improved pharmaceutical processability, suitable for large-scale manufacturing and clinical use.
Implementation Method 1
A stable amorphous solid dispersion of Compound 1 with hydroxypropyl methylcellulose acetate succinate (HPMCAS) using microprecipitated bulk powder (MBP) technology
Implementation Method 2
A stable amorphous solid dispersion comprising Compound 1 and hydroxypropyl methylcellulose acetate succinate (HPMCAS)
Data Source
AI summary
Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-1-yl)-3-(2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1.